We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

7 hedge funds and large institutions have $780K invested in Biostar Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

33% less capital invested

Capital invested by funds: $1.17M → $780K (-$391K)

36% less funds holding

Funds holding: 117 (-4)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
7
Holders Change
-4
Holders Change %
-36.36%
% of All Funds
0.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
1
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$706K +$12K +1,257 +1%
SIM
2
Spark Investment Management
New York
$22K -$7.33K -771 -22%
Citadel Advisors
3
Citadel Advisors
Florida
$17K +$20.3K +2,135 New
California Public Employees Retirement System
4
California Public Employees Retirement System
California
$15K
Morgan Stanley
5
Morgan Stanley
New York
$12K +$13.6K +1,428 +5,100%
UBS Group
6
UBS Group
Switzerland
$7K +$8.62K +906 New
Bank of America
7
Bank of America
North Carolina
$1K
BCM
8
Bridgeway Capital Management
Texas
-$71K -6,286 Closed
EGA
9
Eagle Global Advisors
Texas
-$33K -2,940 Closed
Jane Street
10
Jane Street
New York
-$21K -1,853 Closed
Two Sigma Investments
11
Two Sigma Investments
New York
-$16K -1,429 Closed
TRCT
12
Tower Research Capital (TRC)
New York
-$5K -458 Closed

BSPM Hedge Fund Activity: Q4 2014 in Review

7 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q4 2014, worth a combined $780K — down 33% from $1.17M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BSPM and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $20.3K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $71K sold.

  • 7 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q4 2014, down from 11 in Q3 2014.
  • Funds reported $780K of Biostar Pharmaceuticals, Inc. stock for Q4 2014, down 33% quarter-over-quarter.
  • 2 funds opened new Biostar Pharmaceuticals, Inc. positions in Q4 2014 and 5 closed out, a net change of -3 holders.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q4 2014 was Citadel Advisors, an estimated $20.3K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q4 2014 was Bridgeway Capital Management, an estimated $71K sold.

Based on aggregated 13F filings for Q4 2014.